Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dbcc Research LLC maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, which is being handled by a distinct examiner. MAHLUM, JONATHAN DAVIS is the busiest examiner for the company with 1 pending office action under review.
The prosecution is confined to 1 distinct art unit, reflecting a focused application of biotechnology and pharmaceutical principles. With a distinct examiner and the pending office action, the company's current patent office interaction is highly centralized. This means the outcome for the pending office action depends entirely on the feedback from MAHLUM, JONATHAN DAVIS within that specific art unit.
For practitioners, this data indicates a low volume of active prosecution for Dbcc Research LLC at this time. The pending matter requires a targeted approach to satisfy the requirements of the 1 distinct examiner involved. Because there are no other pending actions or examiners, the current strategy is focused solely on the pending office action in the Biotechnology & Pharmaceuticals sector.
The busiest examiner pending count of 1 confirms that the company's immediate patent goals are tied to a single review process. Reviewing the examiner's history within the Biotechnology & Pharmaceuticals space can help anticipate potential hurdles. Monitoring the status of the pending office action is vital for timely adjustments to the broader intellectual property strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18607228 | METHODS FOR TREATING LEIGH SYNDROME | MAHLUM, JONATHAN DAVIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18607228 | METHODS FOR TREATING LEIGH SYNDROME | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18607228 | METHODS FOR TREATING LEIGH SYNDROME | MAHLUM, JONATHAN DAVIS | 1625 | §102§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDbcc Research LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jonathan Davis Mahlum has the most, with 1 of Dbcc Research LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
